The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Janux Therapeutics Inc (NASDAQ: JANX) was $22.58 for the day, down -6.62% from the previous closing price of $24.18. In other words, the price has decreased by -$6.62 from its previous closing price. On the day, 1.22 million shares were traded. JANX stock price reached its highest trading level at $24.665 during the session, while it also had its lowest trading level at $22.495.
Ratios:
Our analysis of JANX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 58.47 and its Current Ratio is at 58.47. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Raymond James on July 11, 2025, initiated with a Outperform rating and assigned the stock a target price of $65.
On December 03, 2024, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $63 to $70. BTIG Research reiterated its Buy rating for the stock on December 03, 2024, while the target price for the stock was revised from $82 to $100.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 01 ’25 when Meyer Andrew Hollman sold 3,333 shares for $32.03 per share. The transaction valued at 106,745 led to the insider holds 82,139 shares of the business.
ANDREW MEYER bought 3,333 shares of JANX for $110,656 on May 01 ’25. On Apr 21 ’25, another insider, Meyer Andrew Hollman, who serves as the Chief Business Officer of the company, sold 3,334 shares for $30.00 each. As a result, the insider received 100,020 and left with 82,139 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 1428324992 and an Enterprise Value of 344641056. For the stock, the TTM Price-to-Sale (P/S) ratio is 143.06 while its Price-to-Book (P/B) ratio in mrq is 1.32. Its current Enterprise Value per Revenue stands at 36.915 whereas that against EBITDA is -3.09.
Stock Price History:
The Beta on a monthly basis for JANX is 2.86, which has changed by -0.37032908 over the last 52 weeks, in comparison to a change of 0.18634176 over the same period for the S&P500. Over the past 52 weeks, JANX has reached a high of $71.71, while it has fallen to a 52-week low of $22.48. The 50-Day Moving Average of the stock is -8.68%, while the 200-Day Moving Average is calculated to be -38.54%.
Shares Statistics:
JANX traded an average of 892.42K shares per day over the past three months and 960280 shares per day over the past ten days. A total of 59.17M shares are outstanding, with a floating share count of 53.58M. Insiders hold about 9.45% of the company’s shares, while institutions hold 110.34% stake in the company. Shares short for JANX as of 1752537600 were 9654389 with a Short Ratio of 10.82, compared to 1749772800 on 10610234. Therefore, it implies a Short% of Shares Outstanding of 9654389 and a Short% of Float of 23.599999999999998.
Earnings Estimates
The market rating for Janux Therapeutics Inc (JANX) is a result of the insights provided by 8.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.39 and low estimates of -$0.99.
Analysts are recommending an EPS of between -$1.32 and -$3.28 for the fiscal current year, implying an average EPS of -$2.09. EPS for the following year is -$2.74, with 9.0 analysts recommending between -$1.35 and -$4.76.
